

SAFETY AND EFFECTIVENESS OF VONOPRAZAN AND AMOXICILLIN DUAL REGIMEN WITH SACCHAROMYCES BOULARDII SUPPLEMENTATION AS A RESCUE THERAPY FOR HELICOBACTER PYLORI INFECTION: A PILOT STUDY

Jing Yu

UEG Week Copenhagen 2023

Poster

Stomach & H. Pylori

October 15, 2023

A 14-day vonoprazan, amoxicillin, and Saccharomyces boulardii regimen achieved 92.6% eradication of Helicobacter pylori in patients with 1–3 prior treatment failures, despite high antibiotic resistance rates.

KEY POINTS

- The study enrolled 68 patients with previous H. pylori eradication failures and treated them with 20 mg vonoprazan twice daily, 750 mg amoxicillin three times daily, and 250 mg Saccharomyces boulardii twice daily for 14 days
- Intention-to-treat eradication rate was 92.6% (63/68) and per-protocol rate was 92.3% (60/65), with no difference based on number of prior treatment failures
- Among tested isolates, clarithromycin resistance was 91.3%, metronidazole resistance was 100%, levofloxacin resistance was 60.9%, and 60.9% were resistant to all three antibiotics
- Eradication rate was significantly higher in patients without anxiety (96.8%) compared to those with anxiety (60.0%, $P = 0.025$), and the authors suggest the regimen may need adjustment for anxious patients
- No severe adverse events occurred, 95.6% of patients showed good compliance, and serological examination showed no significant changes in liver and kidney function

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/3125ff82-743b-11ee-b954-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.